Global Tasigna Market

Tasigna Comprehensive Study by Type (50mg, 100mg, 150mg, 200mg, Others), Patients Type (Adult, Pediatric), Distribution Channel (Online, Offline), End User (Hospital, Drugs Store, Other) Players and Region - Global Market Outlook to 2030

Tasigna Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Tasigna
Nilotinib, popularly known with its trade name TASIGNA, and it is a cancer medicine that interferes with the growth and spread of cancer cells in the human body. It is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old. TASIGNA was approved by Food and Drug Administration (FDA) for pediatric patients who are diagnosed with rare cancer called chronic myeloid leukemia. Novartis Pharmaceuticals Corporation has been at the helm of introducing this medicine. Various companies are developing this medicine with most of them still in the trial phase.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global Tasigna market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market Analyst at AMA Research estimates that Indian Players will contribute the maximum growth to Global Tasigna market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis International AG ( Switzerland), Cayman Chemical Company (United States), Biocon Limited (India), Biotechnica Pharma Global (Algeria), Hetero Drugs Limited (India), Jeil Pharmaceutical Co., Ltd (South Korea), Johnson Matthey PLC (United Kingdom), Natco Pharma Limited (India) and Shilpa Medicare Limited (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Takeda Ltd. (Japan), Pfizer Inc. (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Tasigna market by Type (50mg, 100mg, 150mg, 200mg and Others) and Region.



On the basis of geography, the market of Tasigna has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Patients Type, the sub-segment i.e. Adult will boost the Tasigna market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Tasigna market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Tasigna market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Use in Blood Cancer

Market Growth Drivers:
Rising Chronic Diseases Globally and Increasing Aging Population Worldwide

Challenges:
Common Side Effects of Tasigna such as Skin Rash, Itching, Headache, Nausea, Others are Hindering the Market

Restraints:
High Cost of Drug Development

Opportunities:
Technological Research and Development by the Manufacturers

Market Leaders and their expansionary development strategies
In March 2018, Novartis announced that the US Food and Drug Administration (FDA) expanded the indication for Tasigna(®) (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Novartis has licensed its blood cancer drug, Tasigna (nilotinib), to the United Nations’ Medicines Patent Pool, for use by generic drugmakers.The company has joined the Access to Oncology Medicines coalition, which was formed this month to improve access to cancer medicines in low- and lower middle-income countries.The license is the first for a non-communicable disease drug made available to the pool, joining HIV and COVID-19 licensed technologies.Tasigna is currently FDA-approved as a treatment for patients with chronic myeloid leukemia that is Philadelphia chromosome-positive. The drug is also authorized in the EU for the same indication.


Key Target Audience
Tasigna Manufacturers, Healthcare Research Centers, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors and Other

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • 50mg
  • 100mg
  • 150mg
  • 200mg
  • Others
By Patients Type
  • Adult
  • Pediatric

By Distribution Channel
  • Online
  • Offline

By End User
  • Hospital
  • Drugs Store
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Chronic Diseases Globally
      • 3.2.2. Increasing Aging Population Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Common Side Effects of Tasigna such as Skin Rash, Itching, Headache, Nausea, Others are Hindering the Market
    • 3.4. Market Trends
      • 3.4.1. Increasing Use in Blood Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tasigna, by Type, Patients Type, Distribution Channel, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Tasigna (Value)
      • 5.2.1. Global Tasigna by: Type (Value)
        • 5.2.1.1. 50mg
        • 5.2.1.2. 100mg
        • 5.2.1.3. 150mg
        • 5.2.1.4. 200mg
        • 5.2.1.5. Others
      • 5.2.2. Global Tasigna by: Patients Type (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Pediatric
      • 5.2.3. Global Tasigna by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Tasigna by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Drugs Store
        • 5.2.4.3. Other
      • 5.2.5. Global Tasigna Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Tasigna (Price)
      • 5.3.1. Global Tasigna by: Type (Price)
  • 6. Tasigna: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG ( Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cayman Chemical Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biocon Limited (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biotechnica Pharma Global (Algeria)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Hetero Drugs Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Jeil Pharmaceutical Co., Ltd (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson Matthey PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Natco Pharma Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shilpa Medicare Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Tasigna Sale, by Type, Patients Type, Distribution Channel, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Tasigna (Value)
      • 7.2.1. Global Tasigna by: Type (Value)
        • 7.2.1.1. 50mg
        • 7.2.1.2. 100mg
        • 7.2.1.3. 150mg
        • 7.2.1.4. 200mg
        • 7.2.1.5. Others
      • 7.2.2. Global Tasigna by: Patients Type (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Pediatric
      • 7.2.3. Global Tasigna by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Tasigna by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Drugs Store
        • 7.2.4.3. Other
      • 7.2.5. Global Tasigna Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Tasigna (Price)
      • 7.3.1. Global Tasigna by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tasigna: by Type(USD Million)
  • Table 2. Tasigna 50mg , by Region USD Million (2018-2023)
  • Table 3. Tasigna 100mg , by Region USD Million (2018-2023)
  • Table 4. Tasigna 150mg , by Region USD Million (2018-2023)
  • Table 5. Tasigna 200mg , by Region USD Million (2018-2023)
  • Table 6. Tasigna Others , by Region USD Million (2018-2023)
  • Table 7. Tasigna: by Patients Type(USD Million)
  • Table 8. Tasigna Adult , by Region USD Million (2018-2023)
  • Table 9. Tasigna Pediatric , by Region USD Million (2018-2023)
  • Table 10. Tasigna: by Distribution Channel(USD Million)
  • Table 11. Tasigna Online , by Region USD Million (2018-2023)
  • Table 12. Tasigna Offline , by Region USD Million (2018-2023)
  • Table 13. Tasigna: by End User(USD Million)
  • Table 14. Tasigna Hospital , by Region USD Million (2018-2023)
  • Table 15. Tasigna Drugs Store , by Region USD Million (2018-2023)
  • Table 16. Tasigna Other , by Region USD Million (2018-2023)
  • Table 17. South America Tasigna, by Country USD Million (2018-2023)
  • Table 18. South America Tasigna, by Type USD Million (2018-2023)
  • Table 19. South America Tasigna, by Patients Type USD Million (2018-2023)
  • Table 20. South America Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 21. South America Tasigna, by End User USD Million (2018-2023)
  • Table 22. Brazil Tasigna, by Type USD Million (2018-2023)
  • Table 23. Brazil Tasigna, by Patients Type USD Million (2018-2023)
  • Table 24. Brazil Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 25. Brazil Tasigna, by End User USD Million (2018-2023)
  • Table 26. Argentina Tasigna, by Type USD Million (2018-2023)
  • Table 27. Argentina Tasigna, by Patients Type USD Million (2018-2023)
  • Table 28. Argentina Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 29. Argentina Tasigna, by End User USD Million (2018-2023)
  • Table 30. Rest of South America Tasigna, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Tasigna, by Patients Type USD Million (2018-2023)
  • Table 32. Rest of South America Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 33. Rest of South America Tasigna, by End User USD Million (2018-2023)
  • Table 34. Asia Pacific Tasigna, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Tasigna, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Tasigna, by Patients Type USD Million (2018-2023)
  • Table 37. Asia Pacific Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 38. Asia Pacific Tasigna, by End User USD Million (2018-2023)
  • Table 39. China Tasigna, by Type USD Million (2018-2023)
  • Table 40. China Tasigna, by Patients Type USD Million (2018-2023)
  • Table 41. China Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 42. China Tasigna, by End User USD Million (2018-2023)
  • Table 43. Japan Tasigna, by Type USD Million (2018-2023)
  • Table 44. Japan Tasigna, by Patients Type USD Million (2018-2023)
  • Table 45. Japan Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 46. Japan Tasigna, by End User USD Million (2018-2023)
  • Table 47. India Tasigna, by Type USD Million (2018-2023)
  • Table 48. India Tasigna, by Patients Type USD Million (2018-2023)
  • Table 49. India Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 50. India Tasigna, by End User USD Million (2018-2023)
  • Table 51. South Korea Tasigna, by Type USD Million (2018-2023)
  • Table 52. South Korea Tasigna, by Patients Type USD Million (2018-2023)
  • Table 53. South Korea Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 54. South Korea Tasigna, by End User USD Million (2018-2023)
  • Table 55. Taiwan Tasigna, by Type USD Million (2018-2023)
  • Table 56. Taiwan Tasigna, by Patients Type USD Million (2018-2023)
  • Table 57. Taiwan Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 58. Taiwan Tasigna, by End User USD Million (2018-2023)
  • Table 59. Australia Tasigna, by Type USD Million (2018-2023)
  • Table 60. Australia Tasigna, by Patients Type USD Million (2018-2023)
  • Table 61. Australia Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 62. Australia Tasigna, by End User USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Tasigna, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Tasigna, by Patients Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Tasigna, by End User USD Million (2018-2023)
  • Table 67. Europe Tasigna, by Country USD Million (2018-2023)
  • Table 68. Europe Tasigna, by Type USD Million (2018-2023)
  • Table 69. Europe Tasigna, by Patients Type USD Million (2018-2023)
  • Table 70. Europe Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 71. Europe Tasigna, by End User USD Million (2018-2023)
  • Table 72. Germany Tasigna, by Type USD Million (2018-2023)
  • Table 73. Germany Tasigna, by Patients Type USD Million (2018-2023)
  • Table 74. Germany Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 75. Germany Tasigna, by End User USD Million (2018-2023)
  • Table 76. France Tasigna, by Type USD Million (2018-2023)
  • Table 77. France Tasigna, by Patients Type USD Million (2018-2023)
  • Table 78. France Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 79. France Tasigna, by End User USD Million (2018-2023)
  • Table 80. Italy Tasigna, by Type USD Million (2018-2023)
  • Table 81. Italy Tasigna, by Patients Type USD Million (2018-2023)
  • Table 82. Italy Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 83. Italy Tasigna, by End User USD Million (2018-2023)
  • Table 84. United Kingdom Tasigna, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Tasigna, by Patients Type USD Million (2018-2023)
  • Table 86. United Kingdom Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 87. United Kingdom Tasigna, by End User USD Million (2018-2023)
  • Table 88. Netherlands Tasigna, by Type USD Million (2018-2023)
  • Table 89. Netherlands Tasigna, by Patients Type USD Million (2018-2023)
  • Table 90. Netherlands Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 91. Netherlands Tasigna, by End User USD Million (2018-2023)
  • Table 92. Rest of Europe Tasigna, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Tasigna, by Patients Type USD Million (2018-2023)
  • Table 94. Rest of Europe Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 95. Rest of Europe Tasigna, by End User USD Million (2018-2023)
  • Table 96. MEA Tasigna, by Country USD Million (2018-2023)
  • Table 97. MEA Tasigna, by Type USD Million (2018-2023)
  • Table 98. MEA Tasigna, by Patients Type USD Million (2018-2023)
  • Table 99. MEA Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 100. MEA Tasigna, by End User USD Million (2018-2023)
  • Table 101. Middle East Tasigna, by Type USD Million (2018-2023)
  • Table 102. Middle East Tasigna, by Patients Type USD Million (2018-2023)
  • Table 103. Middle East Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 104. Middle East Tasigna, by End User USD Million (2018-2023)
  • Table 105. Africa Tasigna, by Type USD Million (2018-2023)
  • Table 106. Africa Tasigna, by Patients Type USD Million (2018-2023)
  • Table 107. Africa Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 108. Africa Tasigna, by End User USD Million (2018-2023)
  • Table 109. North America Tasigna, by Country USD Million (2018-2023)
  • Table 110. North America Tasigna, by Type USD Million (2018-2023)
  • Table 111. North America Tasigna, by Patients Type USD Million (2018-2023)
  • Table 112. North America Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 113. North America Tasigna, by End User USD Million (2018-2023)
  • Table 114. United States Tasigna, by Type USD Million (2018-2023)
  • Table 115. United States Tasigna, by Patients Type USD Million (2018-2023)
  • Table 116. United States Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 117. United States Tasigna, by End User USD Million (2018-2023)
  • Table 118. Canada Tasigna, by Type USD Million (2018-2023)
  • Table 119. Canada Tasigna, by Patients Type USD Million (2018-2023)
  • Table 120. Canada Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 121. Canada Tasigna, by End User USD Million (2018-2023)
  • Table 122. Mexico Tasigna, by Type USD Million (2018-2023)
  • Table 123. Mexico Tasigna, by Patients Type USD Million (2018-2023)
  • Table 124. Mexico Tasigna, by Distribution Channel USD Million (2018-2023)
  • Table 125. Mexico Tasigna, by End User USD Million (2018-2023)
  • Table 126. Tasigna: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Tasigna: by Type(USD Million)
  • Table 137. Tasigna 50mg , by Region USD Million (2025-2030)
  • Table 138. Tasigna 100mg , by Region USD Million (2025-2030)
  • Table 139. Tasigna 150mg , by Region USD Million (2025-2030)
  • Table 140. Tasigna 200mg , by Region USD Million (2025-2030)
  • Table 141. Tasigna Others , by Region USD Million (2025-2030)
  • Table 142. Tasigna: by Patients Type(USD Million)
  • Table 143. Tasigna Adult , by Region USD Million (2025-2030)
  • Table 144. Tasigna Pediatric , by Region USD Million (2025-2030)
  • Table 145. Tasigna: by Distribution Channel(USD Million)
  • Table 146. Tasigna Online , by Region USD Million (2025-2030)
  • Table 147. Tasigna Offline , by Region USD Million (2025-2030)
  • Table 148. Tasigna: by End User(USD Million)
  • Table 149. Tasigna Hospital , by Region USD Million (2025-2030)
  • Table 150. Tasigna Drugs Store , by Region USD Million (2025-2030)
  • Table 151. Tasigna Other , by Region USD Million (2025-2030)
  • Table 152. South America Tasigna, by Country USD Million (2025-2030)
  • Table 153. South America Tasigna, by Type USD Million (2025-2030)
  • Table 154. South America Tasigna, by Patients Type USD Million (2025-2030)
  • Table 155. South America Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 156. South America Tasigna, by End User USD Million (2025-2030)
  • Table 157. Brazil Tasigna, by Type USD Million (2025-2030)
  • Table 158. Brazil Tasigna, by Patients Type USD Million (2025-2030)
  • Table 159. Brazil Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 160. Brazil Tasigna, by End User USD Million (2025-2030)
  • Table 161. Argentina Tasigna, by Type USD Million (2025-2030)
  • Table 162. Argentina Tasigna, by Patients Type USD Million (2025-2030)
  • Table 163. Argentina Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 164. Argentina Tasigna, by End User USD Million (2025-2030)
  • Table 165. Rest of South America Tasigna, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Tasigna, by Patients Type USD Million (2025-2030)
  • Table 167. Rest of South America Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 168. Rest of South America Tasigna, by End User USD Million (2025-2030)
  • Table 169. Asia Pacific Tasigna, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Tasigna, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Tasigna, by Patients Type USD Million (2025-2030)
  • Table 172. Asia Pacific Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 173. Asia Pacific Tasigna, by End User USD Million (2025-2030)
  • Table 174. China Tasigna, by Type USD Million (2025-2030)
  • Table 175. China Tasigna, by Patients Type USD Million (2025-2030)
  • Table 176. China Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 177. China Tasigna, by End User USD Million (2025-2030)
  • Table 178. Japan Tasigna, by Type USD Million (2025-2030)
  • Table 179. Japan Tasigna, by Patients Type USD Million (2025-2030)
  • Table 180. Japan Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 181. Japan Tasigna, by End User USD Million (2025-2030)
  • Table 182. India Tasigna, by Type USD Million (2025-2030)
  • Table 183. India Tasigna, by Patients Type USD Million (2025-2030)
  • Table 184. India Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 185. India Tasigna, by End User USD Million (2025-2030)
  • Table 186. South Korea Tasigna, by Type USD Million (2025-2030)
  • Table 187. South Korea Tasigna, by Patients Type USD Million (2025-2030)
  • Table 188. South Korea Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 189. South Korea Tasigna, by End User USD Million (2025-2030)
  • Table 190. Taiwan Tasigna, by Type USD Million (2025-2030)
  • Table 191. Taiwan Tasigna, by Patients Type USD Million (2025-2030)
  • Table 192. Taiwan Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 193. Taiwan Tasigna, by End User USD Million (2025-2030)
  • Table 194. Australia Tasigna, by Type USD Million (2025-2030)
  • Table 195. Australia Tasigna, by Patients Type USD Million (2025-2030)
  • Table 196. Australia Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 197. Australia Tasigna, by End User USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Tasigna, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Tasigna, by Patients Type USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Tasigna, by End User USD Million (2025-2030)
  • Table 202. Europe Tasigna, by Country USD Million (2025-2030)
  • Table 203. Europe Tasigna, by Type USD Million (2025-2030)
  • Table 204. Europe Tasigna, by Patients Type USD Million (2025-2030)
  • Table 205. Europe Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 206. Europe Tasigna, by End User USD Million (2025-2030)
  • Table 207. Germany Tasigna, by Type USD Million (2025-2030)
  • Table 208. Germany Tasigna, by Patients Type USD Million (2025-2030)
  • Table 209. Germany Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 210. Germany Tasigna, by End User USD Million (2025-2030)
  • Table 211. France Tasigna, by Type USD Million (2025-2030)
  • Table 212. France Tasigna, by Patients Type USD Million (2025-2030)
  • Table 213. France Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 214. France Tasigna, by End User USD Million (2025-2030)
  • Table 215. Italy Tasigna, by Type USD Million (2025-2030)
  • Table 216. Italy Tasigna, by Patients Type USD Million (2025-2030)
  • Table 217. Italy Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 218. Italy Tasigna, by End User USD Million (2025-2030)
  • Table 219. United Kingdom Tasigna, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Tasigna, by Patients Type USD Million (2025-2030)
  • Table 221. United Kingdom Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 222. United Kingdom Tasigna, by End User USD Million (2025-2030)
  • Table 223. Netherlands Tasigna, by Type USD Million (2025-2030)
  • Table 224. Netherlands Tasigna, by Patients Type USD Million (2025-2030)
  • Table 225. Netherlands Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 226. Netherlands Tasigna, by End User USD Million (2025-2030)
  • Table 227. Rest of Europe Tasigna, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Tasigna, by Patients Type USD Million (2025-2030)
  • Table 229. Rest of Europe Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 230. Rest of Europe Tasigna, by End User USD Million (2025-2030)
  • Table 231. MEA Tasigna, by Country USD Million (2025-2030)
  • Table 232. MEA Tasigna, by Type USD Million (2025-2030)
  • Table 233. MEA Tasigna, by Patients Type USD Million (2025-2030)
  • Table 234. MEA Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 235. MEA Tasigna, by End User USD Million (2025-2030)
  • Table 236. Middle East Tasigna, by Type USD Million (2025-2030)
  • Table 237. Middle East Tasigna, by Patients Type USD Million (2025-2030)
  • Table 238. Middle East Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 239. Middle East Tasigna, by End User USD Million (2025-2030)
  • Table 240. Africa Tasigna, by Type USD Million (2025-2030)
  • Table 241. Africa Tasigna, by Patients Type USD Million (2025-2030)
  • Table 242. Africa Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 243. Africa Tasigna, by End User USD Million (2025-2030)
  • Table 244. North America Tasigna, by Country USD Million (2025-2030)
  • Table 245. North America Tasigna, by Type USD Million (2025-2030)
  • Table 246. North America Tasigna, by Patients Type USD Million (2025-2030)
  • Table 247. North America Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 248. North America Tasigna, by End User USD Million (2025-2030)
  • Table 249. United States Tasigna, by Type USD Million (2025-2030)
  • Table 250. United States Tasigna, by Patients Type USD Million (2025-2030)
  • Table 251. United States Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 252. United States Tasigna, by End User USD Million (2025-2030)
  • Table 253. Canada Tasigna, by Type USD Million (2025-2030)
  • Table 254. Canada Tasigna, by Patients Type USD Million (2025-2030)
  • Table 255. Canada Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 256. Canada Tasigna, by End User USD Million (2025-2030)
  • Table 257. Mexico Tasigna, by Type USD Million (2025-2030)
  • Table 258. Mexico Tasigna, by Patients Type USD Million (2025-2030)
  • Table 259. Mexico Tasigna, by Distribution Channel USD Million (2025-2030)
  • Table 260. Mexico Tasigna, by End User USD Million (2025-2030)
  • Table 261. Tasigna: by Type(USD/Units)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tasigna: by Type USD Million (2018-2023)
  • Figure 5. Global Tasigna: by Patients Type USD Million (2018-2023)
  • Figure 6. Global Tasigna: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Tasigna: by End User USD Million (2018-2023)
  • Figure 8. South America Tasigna Share (%), by Country
  • Figure 9. Asia Pacific Tasigna Share (%), by Country
  • Figure 10. Europe Tasigna Share (%), by Country
  • Figure 11. MEA Tasigna Share (%), by Country
  • Figure 12. North America Tasigna Share (%), by Country
  • Figure 13. Global Tasigna: by Type USD/Units (2018-2023)
  • Figure 14. Global Tasigna share by Players 2023 (%)
  • Figure 15. Global Tasigna share by Players (Top 3) 2023(%)
  • Figure 16. Global Tasigna share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis International AG ( Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG ( Switzerland) Revenue: by Geography 2023
  • Figure 20. Cayman Chemical Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cayman Chemical Company (United States) Revenue: by Geography 2023
  • Figure 22. Biocon Limited (India) Revenue, Net Income and Gross profit
  • Figure 23. Biocon Limited (India) Revenue: by Geography 2023
  • Figure 24. Biotechnica Pharma Global (Algeria) Revenue, Net Income and Gross profit
  • Figure 25. Biotechnica Pharma Global (Algeria) Revenue: by Geography 2023
  • Figure 26. Hetero Drugs Limited (India) Revenue, Net Income and Gross profit
  • Figure 27. Hetero Drugs Limited (India) Revenue: by Geography 2023
  • Figure 28. Jeil Pharmaceutical Co., Ltd (South Korea) Revenue, Net Income and Gross profit
  • Figure 29. Jeil Pharmaceutical Co., Ltd (South Korea) Revenue: by Geography 2023
  • Figure 30. Johnson Matthey PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Johnson Matthey PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Natco Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 33. Natco Pharma Limited (India) Revenue: by Geography 2023
  • Figure 34. Shilpa Medicare Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Shilpa Medicare Limited (India) Revenue: by Geography 2023
  • Figure 36. Global Tasigna: by Type USD Million (2025-2030)
  • Figure 37. Global Tasigna: by Patients Type USD Million (2025-2030)
  • Figure 38. Global Tasigna: by Distribution Channel USD Million (2025-2030)
  • Figure 39. Global Tasigna: by End User USD Million (2025-2030)
  • Figure 40. South America Tasigna Share (%), by Country
  • Figure 41. Asia Pacific Tasigna Share (%), by Country
  • Figure 42. Europe Tasigna Share (%), by Country
  • Figure 43. MEA Tasigna Share (%), by Country
  • Figure 44. North America Tasigna Share (%), by Country
  • Figure 45. Global Tasigna: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Novartis International AG ( Switzerland)
  • Cayman Chemical Company (United States)
  • Biocon Limited (India)
  • Biotechnica Pharma Global (Algeria)
  • Hetero Drugs Limited (India)
  • Jeil Pharmaceutical Co., Ltd (South Korea)
  • Johnson Matthey PLC (United Kingdom)
  • Natco Pharma Limited (India)
  • Shilpa Medicare Limited (India)
Additional players considered in the study are as follows:
Takeda Ltd. (Japan) , Pfizer Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 189 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tasigna Market Quantitative research analysis
Global Tasigna Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis International AG ( Switzerland), Cayman Chemical Company (United States), Biocon Limited (India), Biotechnica Pharma Global (Algeria), Hetero Drugs Limited (India), Jeil Pharmaceutical Co., Ltd (South Korea), Johnson Matthey PLC (United Kingdom), Natco Pharma Limited (India) and Shilpa Medicare Limited (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Use in Blood Cancer" is seen as one of major influencing trends for Tasigna Market during projected period 2023-2030.
The Tasigna market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Tasigna Market Report?

Have a Query? Click Here

Other Related Reports

Hemostatic Sponge Comprehensive Study by Application (Surgical Wound Care, General Wound Care), End-user (Hospitals, Clinics, Others), Component (Gelatin, Cellulose, Chitosan) Players and Region - Gl...
$ 3500
Bacillus Coagulans Comprehensive Study by Type (Pharmaceutical grade, Food Grade, Others), Application (Pharmaceuticals, Food Industry, Feed Industry, Others), Distribution Channel (Hypermarkets/Supe...
$ 3450
Medical Gas Comprehensive Study by Type (Oxygen, Nitrous Oxide, Medical Air, Others), Application (Hospitals & Clinics, Home Healthcare, Universities & Research Institutions, Pharmaceutical & Biotech...
$ 3500
Surgical Gowns Comprehensive Study by Type (Reusable, Disposable), End Users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Clinics, Others), Distribution Channel (Online Sales, Retail ...
$ 3350
Neuroprosthetics Comprehensive Study by Type (Output Neural Prosthetics, Input Neural Prosthetics), Application (Motor Neuron Disorders, Physiological Disorders, Cognitive Disorders), Technology (Dee...
$ 3650
Dental Biomaterials Comprehensive Study by Type (Metallic Biomaterials, Titanium, Stainless Steel, Chromium Alloys, Other Metallic Biomaterials, Metal-ceramic Biomaterials, Ceramic Biomaterials, Poly...
$ 3750